GSK Expects 2025 Turnover Growth Of 3%-5%, Core EPS Rise Of 6%-8%, And Core Operating Profit Growth Of 6%-8%
2025 Guidance
GSK provides its full-year guidance at constant exchange rates (CER).
- Turnover is expected to increase between 3 to 5 per cent
- Core operating profit is expected to increase between 6 to 8 per cent
- Core earnings per share is expected to increase between 6 to 8 per cent
This guidance is supported by the following turnover expectations for full-year 2025 at CER
- Specialty Medicines – expected increase of a low double-digit per cent in turnover
- Vaccines – expected decrease of a low single-digit per cent in turnover
- General Medicines – expected to be broadly stable for turnover
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。